Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pradaxa

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Idarucizumab is the only anticoagulant reversal agent for dabigatran. Because of its high cost and limited data regarding… Expand
2015
2015
Pradaxa (dabigatran) is a direct thrombin inhibitor approved for prevention of stroke and systemic embolism in patients with non… Expand
2015
2015
Novel oral anticoagulants are effective and safe alternatives to vitamin-K antagonists for anticoagulation therapy. However… Expand
2015
2015
  • P. O'Malley
  • Clinical nurse specialist CNS
  • 2015
  • Corpus ID: 110494
For decades, the basis for anticoagulation therapy has been the inhibition of enzymes at various levels of the coagulation… Expand
Review
2015
Review
2015
Purpose:To critically appraise the evidence on dabigatran etexilate, Pradaxa, as an alternative to warfarin for stroke prevention… Expand
Review
2014
Review
2014
Dabigatran etexilate, an oral direct thrombin inhibitor, was approved by the Food and Drug Administration to reduce the risk of… Expand
  • table 1
  • table 2
  • table 3
2014
2014
The invention relates to a method for preparing a pradaxa intermediate. The method is a chemical synthetic method, a synthesis… Expand
Review
2012
Review
2012
Study Design. The authors present a case report of a 72-year-old man who presented with back pain and lower extremity weakness… Expand
Review
2012
Review
2012
PurposeOral direct factor Xa inhibitors and oral direct thrombin inhibitors are new oral anticoagulants (NOACs) for stroke… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
Summary: Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors… Expand
  • figure 2
  • figure 1